Ankylosing spondylitis (AS) is characterized by inflammation
|
|
- Georgia Manning
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Is Osteoporosis Generalized or Localized to Central Skeleton in Ankylosing Spondylitis? Selda Sarikaya, MD, Aynur Basaran, MD, Yasin Tekin, MD, Senay Ozdolap, MD, and Ozgur Ortancil, MD Background: Osteoporosis at the lumbar spine and at the femur is a well-established complication in ankylosing spondylitis (AS), but the exact mechanism and the distribution of osteoporosis are not known absolutely. Objective: To determine whether the osteoporosis is generalized or localized to central skeleton and to examine the relation between bone mineral density (BMD) and disease activity and radiologic progression in patients with AS. Methods: In this study, 26 patients with AS and 33 healthy controls matched for age and sex were recruited to the study. Hip and forearm BMD were measured by dual energy X-ray absorptiometry (DEXA). Laboratory and clinical disease activity parameters were documented, and anteroposterior sacroiliac radiographs were taken to determine the radiologic progression. Results: The urine deoxypyridinoline levels of the patients with AS were statistically significantly higher (P 0.02) and the serum osteocalcin levels were significantly lower with respect to controls (P 0.03). The femoral neck and femur BMD values and T scores were significantly lower in patients with AS compared with the controls (P 0.019, 0.003, 0.01, and 0.01, respectively). The differences in BMD values and T scores of the distal 1/3 radius between 2 groups were not statistically significant. The relation between BMD and disease activity, and radiologic progression in patients with AS could not detected. Conclusion: Sparing of distal regions such as the as radius suggests that osteoporosis might be due to localized effects of inflammatory activity or immobility rather than a systemic effect. Both increased resorption and decreased formation might be involved in the pathogenesis of osteoporosis. Radius BMD may not be appropriate to evaluate bone loss in patients with AS. Key Words: ankylosing spondylitis, osteoporosis, central skeleton (J Clin Rheumatol 2007;13: 20 24) From the Department of Physical Medicine and Rehabilitation, Zonguldak Karaelmas University Faculty of Medicine, Zonguldak, Turkey. Reprints: Dr. Aynur Basaran, Zonguldak Karaelmas Üniversitesi Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalý, Zonguldak 67600, Turkey. abasaran@med.karaelmas.edu.tr or aynurbasaran@ hotmail.com. Copyright 2007 by Lippincott Williams & Wilkins ISSN: /07/ DOI: /01.rhu Ankylosing spondylitis (AS) is characterized by inflammation of entheses and paravertebral structures leading to bone formation at those sites. 1 Early vertebral bone loss is also a recognized feature of AS, 2 and seems to be associated with severe complications such as vertebral fractures and increased spinal deformity. 3,4 Syndesmophytes and spinal ossifications may result in false increase in bone mineral density (BMD) assessed by conventional posteroanterior dual energy X-ray absorptiometry (DEXA) 5 and may be insufficient to show osteoporosis. Currently, femoral DEXA is thought to be the most accurate method for diagnosis of osteoporosis in AS. 5 8 Similar to other inflammatory arthritides, the role of different factors in the pathogenesis of osteoporosis such as treatment, mobility or physical activity, hormone status, or even the inflammatory process, is not defined completely in AS. 7,9 13 Factors involving local and/or systemic inflammation might result in osteoporosis. Exact mechanism leading to bone loss in vertebrae and new bone formation in syndesmophytes concomitantly is not known. Therefore, it has been suggested the pathologic processes of resorption and bone formation may well occur in close proximity. 8,14 In this study, we aimed to measure hip and forearm BMD with DEXA, to determine whether the osteoporosis is generalized or localized to the central skeleton, to examine bone metabolism and disease activity in AS patients. Also the relation between bone metabolism, BMD, disease activity, and radiologic progression was investigated. MATERIALS AND METHODS During the study period of , 26 patients (5 women, 21 men) diagnosed as AS according to the Modified New York criteria 15 and age- and sex-matched 33 healthy controls (13 women, 20 men) were recruited to the study. Patients with metabolic bone disease (such as Paget disease, osteomalacia, hyperparathyroidism), chronic renal, hepatic and thyroid disease, hormone disorders, medication affecting bone metabolism (such as corticosteroids, bisphosphonates), and postmenopausal women were excluded. In this study, AS patients with peripheral arthritis were excluded. All patients and the control group had sedentary lifestyles with low physical activity (e.g., office workers, housewives). BMD was measured from hip and forearm on the nondominant side by DEXA (Hologic QDR 4500W, Hologic, Bedford, MA), which has a mean precision error of 1% for 20 JCR: Journal of Clinical Rheumatology Volume 13, Number 1, February 2007
2 JCR: Journal of Clinical Rheumatology Volume 13, Number 1, February 2007 Osteoporosis in Ankylosing Spondylitis the forearm and hip. The reference values of BMD for women and men were provided by the manufacturer. The results were recorded as g/cm 2 and T score. T scores 1 were classified as normal, 1 and 2.5 were classified as osteopenia, and 2.5 were classified as osteoporosis according to World Health Organization (WHO) osteoporosis classification. 16 The femur T score accepted was the lowest value measured anywhere except the Ward triangle. The laboratory activity was assessed by erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), the clinical disease activity was evaluated by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 17 and the functional status measurement was made by Bath Ankylosing Spondylitis Functional Index (BASFI). 18 An anteroposterior radiograph of the pelvis was taken in all patients with AS. Radiologic progression was evaluated by Bath Ankylosing Spondylitis Radiology Index (BASRI). 19 A single investigator assessed all radiographs. Serum concentrations of osteocalcin (OC), parathyroid hormone (PTH), calcium and phosphate and urinary deoxypyridinoline (DPD) and daily urinary calcium excretion levels were measured to evaluate the bone metabolism. Samples for serum and second voided urine were collected at 8:00 to 10:00 a.m. after overnight fasting. Urine is collected for the measurement of urine calcium excretion. Serum samples were stored at 40 C until assayed. Serum calcium and phosphate were measured using spectrophotometry (Cobas Integra 800, Roche, Indianapolis, IN). The OC and PTH levels were determined using a chemiluminescent immunoassay (Elecsys 2010, Roche). Urine DPD was measured with a solid phase chemiluminescent enzyme labeled immunoassay (Immulite One, BioDPC). ESR was determined by the Westergreen method. CRP was determined by latex agglutination method (Plasmatec, UK). Sample size calculation was performed according to T scores between 2 groups. To detect a difference of 0.2, 34 patients (17 patients in each group) were required (P 0.05, power 0.80). Parametric and nonparametric variables between patients were compared using Student t test for independent samples and Mann Whitney U test, respectively. 2 test was used for frequencies in cross-tables. Pearson r and Spearman correlation coefficients were used to assess correlations among laboratory and clinical disease activity parameters, functional status, bone turnover markers, BMD of hip, and T scores, as appropriate. Statistical calculations were performed using SPSS for Windows 11.5 (SPSS Inc.). Statistical significance level was set to TABLE 1. Clinical and Laboratory Characteristics of AS Patients and Controls AS (n 26) Controls (n 33) P Age (y) BMI (kg/m 2 ) DPD (nm/mm 6.10 ( ) 5.0 ( ) 0.02 creatinine)* OC (ng/ml) Calcium (mg/dl) Phosphorus (mg/dl) Urine calcium/d (mg/24 h) PTH (pg/ml) CRP (mg/l)* 0 (0 4) 0 (0 1) ESR (mm/h) AS: ankylosing spondylitis; BMI: body mass index; DPD: deoxypyridinoline; OC: osteocalcin; PTH: parathyroid hormone; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate. *Median (min max). All other values were expressed as mean SD. Statistically significant. RESULTS Clinical and laboratory characteristics of patients and controls are summarized in Table 1. The urine DPD levels of the patients with AS were statistically significantly higher than those in the control subjects (P 0.02). The serum OC levels were significantly lower with respect to controls (P 0.03). The differences between the serum PTH, calcium, phosphorus and urine daily calcium excretion levels were not statistically significant. The biologic markers of disease activity (CRP and ESR) were significantly higher in AS group (P and 0.002, respectively). BASDAI, BASFI, BASRI scores of AS patients were summarized in Table 2. Mean BMD values and T scores in patients with AS and control subjects are given in Table 3. The femoral neck and femur BMD values were significantly lower in patients with AS compared with the controls (P and 0.003, respectively). The difference between the femoral neck and femur T scores of 2 groups were also statistically significant (P 0.01 and 0.01, respectively) with lower levels in the AS group. The differences in BMD and T scores of distal 1/3 radius between the 2 groups were not significant. Osteoporosis classifications according to femur and radius measurements are shown in Table 4. The ratio of patients with low bone density (osteopenia and osteoporosis) at femur in AS patients (76.9%) was significantly higher than that in controls (33.3%, P 0.001). However, the difference in the ratio of low bone density at the distal 1/3 radius between the 2 groups was not significant. Correlation coefficients between bone turnover markers, biologic and clinical parameters of disease activity, functional status, hip BMD values, and T scores were analyzed. There was no correlation between biologic parameters of inflammation (CRP, ESR) and bone turnover markers (OC TABLE 2. BASDAI, BASFI, and BASRI Scores of AS Patients AS (n 26) BASDAI BASFI BASRI sacroiliac* 3.5 (2 4) BASRI lomber* 2 (1 4) AS: ankylosing spondylitis; BASDAI: bath ankylosing spondylitis disease activity index; BASFI: bath ankylosing spondylitis functional index; BASRI: bath ankylosing spondylitis radiology index. *Median (min max). All other values were expressed as mean SD Lippincott Williams & Wilkins 21
3 Sarikaya et al JCR: Journal of Clinical Rheumatology Volume 13, Number 1, February 2007 TABLE 3. Mean BMD Values and T Scores in Patients With AS and Control Subjects AS (n 26) Controls (n 33) P Total femur BMD (g/cm 2 ) * Femoral neck BMD (g/cm 2 ) * 1/3 distal radius BMD (g/cm 2 ) Femur T score * Femoral neck T score * 1/3 distal radius T score 1.50 ( 3.70 to 1.30) 1.30 ( 2.40 to 0.50) AS: ankylosing spondylitis; BMD: bone mineral density. *Statistically significant. Median (min max). All other values were expressed as mean SD. TABLE 4. Osteoporosis Classification of the Patients and Control Subjects AS (n 26) Controls (n 33) P Femur Normal (%) 6 (23.1) 22 (66.7) 0.001* Osteopenia osteoporosis (%) 20 (76.9) 11 (33.3) Radius Normal (%) 8 (30.8) 11 (33.3) 0.83 Osteopenia osteoporosis (%) 18 (69.2) 22 (66.7) AS: ankylosing spondylitis; OP: osteoporosis. *Statistically significant. and DPD). Correlation between bone turnover markers and either BASDAI or BASFI scores was not detected (all P 0.05). Additionally, there was no correlation between bone turnover markers and either femur/femoral neck BMD values or T scores (all P 0.05). There were no correlations between sacroiliac BASRI score and either femur/femoral neck BMD values or T scores (all P 0.05). DISCUSSION In inflammatory arthropathies, the mechanism of bone loss is complex and seems to be multifactorial. The factors responsible from bone loss include medication (especially corticosteroids), hormone disorders, genetics, inflammation, and decreased mobility or physical activity. 2,12,20,21 Low bone density has been well documented in patients with AS. 8,9,22,23 Clinically osteopenia or osteoporosis has been recognized in 20% 60% of patients. 8 Also it has been shown that patients with active disease without hip involvement as well as patients with hip arthritis had low BMD at the femoral neck. 2,12,24 Therefore it was hypothesized that the inflammatory process could be responsible for generalized osteoporosis. 9,25,26 In accordance with previous studies, 8,27 29 however, we did not observe low BMD at the radius. OP at the femur, while the radius is spared, might be explained by a close relationship of femur to sacroiliac joints rather than systemic inflammatory involvement, in the patients without hip arthritis. In our study, sparing of the distal radius BMD showed that osteoporosis in AS is not generalized. Local factors might also be responsible. According to these results, 22 distal radius BMD should not be used to evaluate the cortical bone loss, instead of femur BMD in AS patients for whom femur BMD was not available (difficulty in positioning, femoral arthroplasty, etc.). In our study, we have observed the incidence of osteoporosis/osteopenia ratio higher than expected values in the control group, as well as the patients. There is no study demonstrating normal values in our population. However, BMD values (g/cm 2 ) are statistically significantly lower in AS patients suggesting that there is additional bone loss in femur BMD, while the radius is spared. Although osteoporosis at the lumbar spine and femur is well established, the mechanism and factors are not known absolutely in AS. It is thought that osteoporosis in AS is related with increased bone resorption associated with inflammation The role of osteoblasts in new bone formation in AS is not defined completely. The results of crosssectional studies are contradictory. Some of the studies have documented low levels of OC, 10,34,35 while some documented normal levels, 12,36,37 and some of them documented high levels 8,38 in patients with AS. In addition to this the relationship between OC and inflammation has not been documented. 8 Recently, in a case control study of 29 patients with AS, El Maghraoui et al 39 showed that serum OC levels were significantly lower in AS patients than those in healthy controls. They hypothesized that decreased formation may play a role in the pathogenesis of osteoporosis. In our study serum OC levels were significantly lower in AS patients (P 0.03). Additionally urine DPD levels were significantly higher in AS patients than those in controls (P 0.02) consistent with previous reports. 36,37 These results suggest that decreased bone formation and increased resorption might be involved in the pathogenesis of osteoporosis in patients with AS. Studies of bone resorption markers and disease activity have shown that the excretion of pyridinoline crosslinks is correlated with ESR 36,37 and CRP 23,33 indicating that patients with active disease could have a higher risk of bone loss. These results together support that increased inflammatory activity in AS leads to increased bone resorption and thus decreased bone density. 8 Nevertheless, studies investigating for a relationship between BMD and inflammatory activity in AS patients have reported negative results. 29,36 Karberg et al 8 reported that BMD was not correlated with disease activity (assessed by BASDAI) and inflammation (measured by CRP) in 2007 Lippincott Williams & Wilkins
4 JCR: Journal of Clinical Rheumatology Volume 13, Number 1, February 2007 Osteoporosis in Ankylosing Spondylitis patients with AS. Similarly there was no statistically significant relationship between urinary DPD and the BASDAI score or CRP levels. In our study, there was no correlation between disease activity (assessed by CRP, ESR, and BASDAI score) and bone turnover (assessed by OC and DPD levels). In addition to this, there was no correlation between bone turnover markers (OC and DPD levels) and BMD (total and femoral, neck BMD values and T scores), consistent with Karberg s study. In a prospective study of Gratacos et al, with a mean follow-up of 19 months, a significant reduction in bone mass in the lumbar spine and femoral neck in patients with active AS has been documented. 9 In our study, lack of correlation between BMD and clinical or biologic activity of the disease, as assessed by BASDAI and CRP, might be explained as that serum levels of biologic markers reflect the situation at a given time point, whereas BMD values reflect the cumulative influence of the disease over time. 6 In addition to this, relatively low levels of disease activity in our patients might be responsible for these results also. El Maghraoui et al 39 showed a negative significant statistical correlation with BMD and BASMI and BASRI, which show long-term effects and severity of disease activity. However we could not demonstrate a correlation between sacroiliac BASRI score and BMD. In conclusion, osteoporosis is the result of complex pathophysiologic mechanisms involving disease activity and inflammatory process in AS. Sparing of distal regions as radius might be due to localized effects of inflammatory activity rather than systemic effect. Therefore, radius BMD measurement might not be appropriate to evaluate bone loss in patients with AS. REFERENCES 1. Gilgil E, Kacar C, Tuncer T, et al. The association of syndesmophytes with vertebral bone mineral density in patients with ankylosing spondylitis. J Rheumatol. 2005;32: Will R, Palmer R, Bhalla AK, et al. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet. 1989;2: Ralston SH, Urquhart GD, Brzeski M, et al. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ. 1990;300: Cooper C, Carbone L, Michet CJ, et al. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol. 1994; 21: Bessant R, Harris C, Keat A. Audit of the diagnosis, assessment, and treatment of osteoporosis in patients with ankylosing spondylitis. J Rheumatol. 2003;30: Wendling D. Bone loss in ankylosing spondylitis: can we put the puzzle together? J Rheumatol. 2005;32: Meirelles ES, Borelli A, Camargo OP. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol. 1999;18: Karberg K, Zochling J, Sieper J, et al. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol. 2005;32: Gratacos J, Collado A, Pons F, et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a follow-up study. Arthritis Rheum. 1999;42: Franck H, Keck E. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis. 1993;52: Jimenez-Balderas FJ, Tapia-Serrano R, Madero-Cervera JI, et al. Ovarian function studies in active ankylosing spondylitis in women. Clinical response to estrogen therapy. J Rheumatol. 1990;17: Lee YS, Schlotzhauer T, Ott SM, et al. Skeletal status of men with early and late ankylosing spondylitis. Am J Med. 1997;103: Sivri A, Kilinc S, Gokce-Kutsal Y, et al. Bone mineral density in ankylosing spondylitis. Clin Rheumatol. 1996;15: Aufdermaur M. Pathogenesis of square bodies in ankylosing spondylitis. Ann Rheum Dis. 1989;48: Goei The HS, Steven MM, van der Linden SM, et al. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol. 1985;24: Kanis JA. Diagnosis of osteoporosis. Osteoporos Int. 1997;7(Suppl 3): S108 S Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21: Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21: MacKay K, Mack C, Brophy S, et al. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. 1998;41: MacDonald BR, Gowen M. Cytokines and bone. Br J Rheumatol. 1992;31: Laan RF, van Riel PL, van de Putte LB. Bone mass in patients with rheumatoid arthritis. Ann Rheum Dis. 1992;51: Lange U, Kluge A, Strunk J, et al. Ankylosing spondylitis and bone mineral density what is the ideal tool for measurement? Rheumatol Int. 2005;26: El Maghraoui A, Borderie D, Cherruau B, et al. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol. 1999;26: Bronson WD, Walker SE, Hillman LS, et al. Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol. 1998;25: Gough A, Sambrook P, Devlin J, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol. 1998;25: Dolan AL, Moniz C, Dasgupta B, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum. 1997;40: Devogelaer JP, Maldague B, Malghem J, et al. Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single- and dual-photon absorptiometry and with quantitative computed tomography. Arthritis Rheum. 1992;35: Leszczynski P, Lacki JK, Mackiewicz SH. Osteoporosis in ankylosing spondylitis: comparison of dual-energy X-ray absorptiometry (DXA) and quantitative ultrasonography (QUS). Przegl Lek. 2003;60: Ozdolap S, Sarikaya S, Akdag B. Influence of disease activity and chronicity on bone mineral density in ankylosing spondylitis. Acta Rheumatologica Turcica. 2004;19: Acebes C, de la Piedra C, Traba ML, et al. Biochemical markers of bone remodeling and bone sialoprotein in ankylosing spondylitis. Clin Chim Acta. 1999;289: Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol. 2004;31: El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine. 2004;71: Lange U, Jung O, Teichmann J, et al. Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos Int. 2001;12: Speden DJ, Calin AI, Ring FJ, et al. Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol. 2002;29: Mitra D, Elvins DM, Collins AJ. Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures. J Rheumatol. 1999;26: Lippincott Williams & Wilkins 23
5 Sarikaya et al JCR: Journal of Clinical Rheumatology Volume 13, Number 1, February Toussirot E, Ricard-Blum S, Dumoulin G, et al. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology (Oxford). 1999;38: Marhoffer W, Stracke H, Masoud I, et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis. 1995;54: Grisar J, Bernecker PM, Aringer M, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol. 2002;29: El Maghraoui A, Tellal S, Chaouir S, et al. Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis. Clin Rheumatol. 2005;24: Lippincott Williams & Wilkins
Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
c Additional supplemental tables 1 and 2 are published online only at http://ard.bmj. com/content/vol68/issue2 1 Centocor Research and Development, Inc., Malvern, Pennsylvania, USA; 2 University Hospital
More informationNon-commercial use only
The relation between disease activity, vitamin D levels and bone mineral density in men patients with ankylosing spondylitis Ihsane Hmamouchi, 1,2 Fadoua Allali, 1,2 Btissam El Hamdaoui, 1 Hanae Amine,
More informationBone mineral density and vertebral compression fracture rates in ankylosing spondylitis
Annals of the Rheumatic Diseases 1994; 53: 117-121 117 Rheumatology, Whipps Cross Hospital, Leytonstone, London, United S Donnelly D V Doyle A Denton I Rolfe Human Metabolism, University of Sheffield Medical
More informationVitamin D levels in patients with ankylosing spondylitis: Is it related to disease activity?
Original Article Vitamin D levels in patients with ankylosing spondylitis: Is it related to disease activity? Burhan Fatih Kocyigit 1, Ahmet Akyol 2 ABSTRACT Objective: Ankylosing Spondylitis (AS) is an
More informationFrequency of low bone mineral density in spondyloarthropathy presenting at a tertiary care hospital
973 ORIGINAL ARTICLE Frequency of low bone mineral density in spondyloarthropathy presenting at a tertiary care hospital Lubna Nazir, Shafique Rehman, Amir Riaz, Mohammad Saeed, Tahira Perveen Abstract
More informationResearch Article Serum Vitamin D and Pyridinoline Cross-Linked Carboxyterminal Telopeptide of Type I Collagen in Patients with Ankylosing Spondylitis
BioMed Research International Volume 2015, Article ID 543806, 6 pages http://dx.doi.org/10.1155/2015/543806 Research Article Serum Vitamin D and Pyridinoline Cross-Linked Carboxyterminal Telopeptide of
More informationHigh prevalence of low bone mineral density in patients within 10 years of onset of Ankylosing spondylitis: a systematic review
High prevalence of low bone mineral density in patients within 10 years of onset of Ankylosing spondylitis: a systematic review M.A.C. van der Weijden T.A.M. Claushuis T. Nazari W.F. Lems B.A.C. Dijkmans
More informationHigh frequency of vertebral fractures in early Spondylarthropathies
Chapter 4 High frequency of vertebral fractures in early Spondylarthropathies M.A.C. van der Weijden I.E. van der Horst-Bruinsma J.C. van Denderen B.A.C. Dijkmans M.W. Heymans W.F. Lems Osteoporosis International.
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationDoes active treatment of rheumatoid arthritis limit disease-associated bone loss?
Rheumatology 2002;41:1047 1051 Does active treatment of rheumatoid arthritis limit disease-associated bone loss? A. L. Dolan, C. Moniz 1, H. Abraha 1 and P. Pitt 2 Department of Rheumatology, Queen Elizabeth
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationContractor Number 03201
Local Coverage Article for Bone Mass Measurements Coverage - 2012 CPT Updates (A51577) Contractor Information Contractor Name Noridian Administrative Services, LLC opens in new window Contractor Number
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationKey words Ankylosing spondylitis, radiographic scoring methods, intra- and interobserver reliability, BASRI, msasss.
Radiological scoring methods for ankylosing spondylitis: a comparison between the Bath Ankylosing Spondylitis Radiology Index and the modified Stoke Ankylosing Spondylitis Spine Score F. Salaffi 1, M.
More informationPerformance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationComparison of Bone Density of Distal Radius With Hip and Spine Using DXA
ORIGINAL ARTICLE Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA Leila Amiri 1, Azita Kheiltash 2, Shafieh Movassaghi 1, Maryam Moghaddassi 1, and Leila Seddigh 2 1 Rheumatology
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationOsteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?
A New Type of Patient Rafat Faraawi, MD, FRCP(C), FACP Until recently, the diagnosis of osteoporosis in men was uncommon and, when present, it was typically described as a consequence of secondary causes.
More informationLow bone mineral density predicts the formation of new syndesmophytes in patients with axial spondyloarthritis
Kim et al. Arthritis Research & Therapy (2018) 20:231 https://doi.org/10.1186/s13075-018-1731-8 RESEARCH ARTICLE Open Access Low bone mineral density predicts the formation of new syndesmophytes in patients
More informationBone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases
Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral
More informationConflict of Interest. Objectives. Learner Outcome
Foundations of Orthopaedic Nursing Care, Part Four: Metabolic Bone Disease, highlighting Osteoporosis and Paget s Disease Conflict of Interest I hereby certify that, to the best of my knowledge, no aspect
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy
More informationObjectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.
Objectives Discuss bone health and the consequences of osteoporosis on patients medical and disability status. Discuss the pathophysiology of osteoporosis and major risk factors. Assess the major diagnostic
More information5/4/2018. Outcome Measures in Spondyloarthritis. Learning Objectives. Outcome Measures Clinical Outcome Assessments
Outcome Measures in Spondyloarthritis Marina N Magrey MD Associate Professor Case Western Reserve University School of Medicine at MetroHealth Medical Center Learning Objectives What are outcome measures
More informationINTRODUCTION. Original Article
J Bone Metab 2015;22:135-141 http://dx.doi.org/10.11005/jbm.2015.22.3.135 pissn 2287-6375 eissn 2287-7029 Original Article Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationIndex. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.
Rheum Dis Clin N Am 32 (2006) 775 780 Index Note: Page numbers of article titles are in boldface type. A AACE (American Association of Clinical Endocrinologists), bone mineral density recommendations of,
More informationDXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi
DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationOmnisense: At Least As Good As DXA
Omnisense: At Least As Good As DXA The following document summarizes a series of clinical studies that have been conducted to compare between different qualities of the Sunlight support the claim that
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationLUMBAR IS IT IMPORTANT? S. Tantawy,, M.D.
بسم االله الرحمن الرحيم DEXA LATERAL LUMBAR IS IT IMPORTANT? By S. Tantawy,, M.D. Osteopenia,, bone mineral deficiency in the absence of fracture, is an indicator of the bone structural integrity and compared
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationBiomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis
Taylan et al. BMC Musculoskeletal Disorders 2012, 13:191 RESEARCH ARTICLE Open Access Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationAwaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page
f #3 Awaisheh Abdullah Alaraj Mousa Al-Abbadi 1 Page *This sheet was written from Section 1 s lecture, in the first 10 mins the Dr. repeated all the previous material relating to osteoporosis from the
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationBone Mineral Densitometry with Dual Energy X-Ray Absorptiometry
Bone Mineral Densitometry with Dual Energy X-Ray Absorptiometry R Gilles, Laurentius Ziekenhuis Roermond 1. Introduction Osteoporosis is characterised by low bone mass, disruption of the micro-architecture
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationBuilding Bone Density-Research Issues
Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationPrevalence of Osteoporosis p. 262 Consequences of Osteoporosis p. 263 Risk Factors for Osteoporosis p. 264 Attainment of Peak Bone Density p.
Dedication Preface Acknowledgments Continuing Education An Introduction to Conventions in Densitometry p. 1 Densitometry as a Quantitative Measurement Technique p. 2 Accuracy and Precision p. 2 The Skeleton
More informationBone Mineral Density in Thai Patients with Chronic Hepatitis C, before and after Treatment with Pegylated Interferon/Ribavirin Combination ABSTRACT
Original Article 73 before and after Treatment with Pegylated Interferon/Ribavirin Combination Bunchorntavakul C 1 Chotiyaputta W 1 Sriussadaporn S 2 Tanwandee T 1 ABSTRACT Background: Loss of bone mineral
More informationBone Mineral Density Studies in Adult Populations
Bone Mineral Density Studies in Adult Populations Last Review Date: July 14, 2017 Number: MG.MM.RA10aC6 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationNutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio
Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development
More informationEuropean Journal of Endocrinology (1997) ISSN
European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationOsteoporosis International. Original Article. Bone Mineral Density and Vertebral Fractures in Men
Osteoporos Int (1999) 10:265 270 ß 1999 International Osteoporosis Foundation and National Osteoporosis Foundation Osteoporosis International Original Article Bone Mineral Density and Vertebral Fractures
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism
Southern Derbyshire Shared Care Pathology Guidelines Primary Hyperparathyroidism Please use this Guideline in Conjunction with the Hypercalcaemia Guideline Definition Driven by hyperfunction of one or
More informationJanuary 19, 2015 by. Nisha Nigil Haroon MBBS, MD, DipNB (Internal Medicine), DM (Endocrinology), CCD
Alterations of bone mineral density, microarchitecture and strength in patients with ankylosing spondylitis: a cross-sectional study using high-resolution peripheral quantitative computerized tomography
More informationPrevalence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures
Malochet-Guinamand et al. BMC Musculoskeletal Disorders (2017) 18:357 DOI 10.1186/s12891-017-1718-7 RESEARCH ARTICLE Open Access Prevalence and risk factors of low bone mineral density in spondyloarthritis
More informationOsteoporosis Screening and Treatment in Type 2 Diabetes
Osteoporosis Screening and Treatment in Type 2 Diabetes Ann Schwartz, PhD! Dept. of Epidemiology and Biostatistics! University of California San Francisco! October 2011! Presenter Disclosure Information
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF NEW MEDICINAL PRODUCTS IN THE TREATMENT OF PRIMARY OSTEOPOROSIS
European Medicines Agency Evaluation of Medicines for Human Use London, 14 December 2005 Doc. Ref. CPMP/EWP/552/95 Rev. 2 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE EVALUATION
More informationQCT BMD Imaging vs DEXA BMD Imaging
QCT BMD Imaging vs DEXA BMD Imaging by Charles (Chuck) Maack Prostate Cancer Advocate/Activist Disclaimer: Please recognize that I am not a Medical Doctor. I have been an avid student researching and studying
More informationAssessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis
140 EXTENDED REPORT Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis A van Tubergen, R Landewé, L Heuft-Dorenbosch,
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationOsteoporosis: Risk Factors, Diagnostic Methods And Treatment Options
ISPUB.COM The Internet Journal of Academic Physician Assistants Volume 1 Number 1 Osteoporosis: Risk Factors, Diagnostic Methods And Treatment Options K Ihrke Citation K Ihrke.. The Internet Journal of
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationBone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes
Klingberg et al. Arthritis Research & Therapy 2013, 15:R179 RESEARCH ARTICLE Open Access Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes
More informationO. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster
DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationA Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman
A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman JY Han, et al CASE REPORT http://dx.doi.org/10.11005/jbm.2012.19.2.153 Vol. 19, No. 2, 2012 A Case of Cushing Syndrome
More informationClinical Study Comparison of QCT and DXA: Osteoporosis Detection Rates in Postmenopausal Women
International Endocrinology Volume 3, Article ID 895474, 5 pages http://dx.doi.org/.55/3/895474 Clinical Study Comparison of QCT and DXA: Osteoporosis Detection Rates in Postmenopausal Women Na Li, Xin-min
More informationTHE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G)
British Journal of Rheumatology 1996;35:66-71 THE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G) S. D. JONES, A. STEINER,* S. L. GARRETT and A. CALIN Royal National Hospital for Rheumatic Diseases,
More information2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Jacques P. Brown, Robert G. Josse, for the Scientific Advisory Council of the Osteoporosis Society of Canada
More informationEffects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis
Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis Mohamed Yassin 1 Ashraf T. Soliman2, Mohamed O. Abdelrahman3, Vincenzo De Sanctis 4 Departments of, 1 Hematology 2Pediatric
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationSerum sclerostin as a possible biomarker in ankylosing spondylitis: a casecontrol
Serum sclerostin as a possible biomarker in ankylosing spondylitis: a casecontrol study Fabio Massimo Perrotta 1, MD, Fulvia Ceccarelli 2, MD, PhD, Cristiana Barbati 2, PhD, Tania Colasanti 2, PhD, Antonia
More informationElena Castellano, Roberto Attanasio, Laura Gianotti, Flora Cesario, Francesco Tassone, and Giorgio Borretta
ORIGINAL ARTICLE Forearm DXA Increases the Rate of Patients With Asymptomatic Primary Hyperparathyroidism Meeting Surgical Criteria Elena Castellano, Roberto Attanasio, Laura Gianotti, Flora Cesario, Francesco
More informationBreast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield
Breast Cancer and Bone Health Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield Breast Cancer and Bone Health Normal Bone Health Impact of Cancer Therapies on Bone Health Therapeutic
More informationGender Differences in Clinical Features and Anti-TNF Agent Use in Korean Ankylosing Spondylitis Patients
Journal of Rheumatic Diseases Vol. 19, No. 3, June, 2012 http://dx.doi.org/10.4078/jrd.2012.19.3.132 Original Article Gender Differences in Clinical Features and Anti-TNF Agent Use in Korean Ankylosing
More informationUnderstanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now?
Understanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now? Steven M. Petak, MD, JD, FACE, FCLM Texas Institute for Reproductive Medicine And Endocrinology, Houston, Texas
More informationDEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN
October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.
More informationBone Densitometry. What is a Bone Density Scan (DXA)? What are some common uses of the procedure?
Scan for mobile link. Bone Densitometry What is a Bone Density Scan (DXA)? Bone density scanning, also called dual-energy x-ray absorptiometry (DXA) or bone densitometry, is an enhanced form of x-ray technology
More informationI mmunosuppressive pulse treatment with intravenous
940 EXTENDED REPORT Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study G Haugeberg, B Griffiths, K B Sokoll, P Emery... See
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationWHAT KEEPS OUR BONES STRONG?
WHAT KEEPS OUR BONES STRONG? The role of diet and lifestyle in osteoporosis prevention Thomas Walczyk PhD, Associate Professor Food Science and Technology Programme Department of Chemistry, Faculty of
More informationConcordance of a Self Assessment Tool and Measurement of Bone Mineral Density in Identifying the Risk of Osteoporosis in Elderly Taiwanese Women
TZU CHI MED J September 2008 Vol 20 No 3 available at http://ajws.elsevier.com/tcmj Tzu Chi Medical Journal Original Article Concordance of a Self Assessment Tool and Measurement of Bone Mineral Density
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More information